CytomX, Pfizer antibody drug deal is worth up to $635M

Pfizer and CytomX Therapeutics agreed to collaborate in the discovery and development of antibody-drug conjugates for cancer using the latter's Probody drug-development technology. The firms will conduct preclinical research, and Pfizer will get the rights to develop and market any chosen ADCs. The deal entitles CytomX to $25 million upfront and as much as $610 million in milestone fees plus sales royalties.

View Full Article in:

Genetic Engineering & Biotechnology News · BioWorld (free content)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Associate Director, Promotion Integrity
Bristol-Myers Squibb
Plainsboro, NJ
Vice President, Medicare Advantage
BCBS-Louisiana
Baton Rouge, LA
Director, Global Integrity and Compliance, Pharmaceuticals
Alcon
Fort Worth, TX